Safety of IV thrombolysis in acute ischemic stroke related to Chagas disease

OBJECTIVE:To determine the rate of symptomatic intracranial hemorrhage (SIH) and in-hospital mortality among patients with acute ischemic stroke related to Chagas disease (CD) treated with IV tissue plasminogen activator (TPA). METHODS:In this retrospective cohort study, consecutive stroke patients treated with IV TPA and routinely tested for CD were retrospectively selected from a single-center, hospital-based, prospective registry of acute stroke patients from 2001 to 2012. Demographic and clinical data were obtained from the registry as well as in-hospital mortality. CT scans were blindly reviewed to assess the occurrence of hemorrhagic transformation. Among acute stroke patients who received IV TPA, we compared those with and without a positive serology for CD. RESULTS:Among 240 patients treated with IV TPA, 174 had serologic testing for CD available. Of those, 24 patients (13.8%) had positive serology for CD. Patients with CD more frequently had heart failure (45.8% vs 14.7%; p < 0.01) and higher admission NIH Stroke Scale scores (19 [15–21] vs 13 [8–19]; p < 0.01) than patients with negative serology. The rates of SIH (4.2% vs 5.3%; odds ratio0.77; 95% confidence interval0.09–6.46; p = 0.99) and in-hospital death (16.7% vs 11.3%; odds ratio1.57; 95% confidence interval0.48–5.12; p = 0.50) were not higher among patients with CD. CONCLUSION:In the largest published series of patients with CD-related stroke treated with IV TPA, we have observed that IV thrombolysis was safely performed and showed no increase of SIH. The diagnosis of CD should not preclude IV thrombolysis in these patients.